Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Younis

Showing results (91-100 of 93) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 93 results.
Journal for Immunotherapy of Cancer|April 5, 2024
Preclinical development of novel PD-L1 tracers and first-in-human study of [<sup>68</sup>Ga]Ga-NOTA-RW102 in patients with lung cancersYou Zhang, Min Cao, Yanfei Wu, et al.
The British Journal of Ophthalmology|October 17, 2018
Unmeasurable small size superficial and deep foveal avascular zone in nanophthalmos: the Collaborative Nanophthalmos OCTA StudyAhmad M Mansour, Michael W Stewart, Salma W Yassine, et al.
Journal for Immunotherapy of Cancer|March 3, 2021
Considerations for treatment duration in responders to immune checkpoint inhibitorsThomas U Marron, Aideen E Ryan, Sangeetha M Reddy, et al.
Pageof 10

Showing results (91-100 of 93) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 93 results.
Journal for Immunotherapy of Cancer|April 5, 2024
Preclinical development of novel PD-L1 tracers and first-in-human study of [<sup>68</sup>Ga]Ga-NOTA-RW102 in patients with lung cancersYou Zhang, Min Cao, Yanfei Wu, et al.
The British Journal of Ophthalmology|October 17, 2018
Unmeasurable small size superficial and deep foveal avascular zone in nanophthalmos: the Collaborative Nanophthalmos OCTA StudyAhmad M Mansour, Michael W Stewart, Salma W Yassine, et al.
Journal for Immunotherapy of Cancer|March 3, 2021
Considerations for treatment duration in responders to immune checkpoint inhibitorsThomas U Marron, Aideen E Ryan, Sangeetha M Reddy, et al.
Pageof 10